OrbiMed’s NanoString Technologies, Inc. NSTG Stock Holding History

OrbiMed’s Portfolio NSTG Stock Details NSTG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-1,157,387	Closed	-$40.2M	–	153
2022 Q1	$40.2M	Buy	1,157,387 +350,287	+43%	+$12.1M	0.65%	46
2021 Q4	$34.1M	Buy	807,100 +251,100	+45%	+$11M	0.44%	63
2021 Q3	$26.7M	Hold	556,000	–	–	0.29%	83
2021 Q2	$36M	Sell	556,000 -66,900	-11%	-$4.25M	0.36%	73
2021 Q1	$40.9M	Sell	622,900 -1,004,000	-62%	-$70.5M	0.38%	71
2020 Q4	$109M	Buy	1,626,900 +443,800	+38%	+$22.3M	0.95%	30
2020 Q3	$52.9M	Sell	1,183,100 -9,300	-0.8%	-$361K	0.66%	44
2020 Q2	$35M	Hold	1,192,400	–	–	0.49%	60
2020 Q1	$28.7M	Buy	+1,192,400	New	+$34.5M	0.48%	55

Other funds holding NSTG

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FAM

Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

PVI

Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

OrbiMed's NSTG Position: Q2 2022 in Review

OrbiMed sold out of NanoString Technologies, Inc. (NSTG) in Q2 2022, closing a stake of 1,157,387 shares — an estimated $40.2M sold.

OrbiMed first reported a position in NSTG in Q1 2020 and held it in 9 quarters. The position peaked at $109M in Q4 2020. 163 funds tracked by Wall St. Rank hold NSTG as of Q2 2022.

OrbiMed reported no remaining NanoString Technologies, Inc. position as of Q2 2022 after selling out during the quarter.
OrbiMed sold 1,157,387 NanoString Technologies, Inc. shares in Q2 2022, an estimated $40.2M.
OrbiMed first reported a position in NanoString Technologies, Inc. in Q1 2020 and held it in 9 quarters.
OrbiMed's NanoString Technologies, Inc. position peaked at $109M in Q4 2020.
163 funds tracked by Wall St. Rank held NanoString Technologies, Inc. as of Q2 2022.

Based on OrbiMed's 13F filing for Q2 2022, filed 15 Aug 2022.